1 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics' research and development activities; clinical trial ini ...

Core Viewpoint - Truist Securities has raised its price target on Cytokinetics, Inc. to $84 from $70 while maintaining a Buy rating, reflecting updated forecasts following the regulatory approval of MYQORZO [1] Group 1: Regulatory Approval and Market Potential - The recent approval of MYQORZO, which features a differentiated label, positions it to become a significant revenue driver in obstructive hypertrophic cardiomyopathy (oHCM) [2] - Truist updated its model to estimate worldwide peak sales for MYQORZO in oHCM at $3.7 billion, slightly below the $3.8 billion consensus estimate [2] Group 2: Revenue Projections and Launch Expectations - A steady launch of MYQORZO is expected to begin in early 2026, with performance anticipated to be at least comparable to the launch trajectory of Camzyos [3] - Truist modeled fiscal 2026 aficamten revenue at $106 million, aligning with consensus expectations [3] - Looking ahead, the analyst projects worldwide peak adjusted total revenue of $4.6 billion in 2035, marginally above the $4.5 billion consensus estimate [3]

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 200 points on Monday [1] Group 2: UniFirst Corporation - Shares of UniFirst Corp rose significantly after receiving an acquisition proposal from Cintas Corporation for $275 per share in cash [1] - The acquisition offer values UniFirst at approximately $5.2 billion, representing a 64% premium over its 90-day average closing price as of December 11, 2025 [1] - UniFirst shares surged by 21.8% to $207.50 during Monday's trading session [1] Group 3: Other Notable Stock Movements - Hycroft Mining Holding Corporation shares jumped by 48.3% to $24.35 following positive drill results from its exploration program [3] - Adeia Inc gained 28.6% to $16.43 after signing a long-term media IP license agreement with Disney and raising its 2025 outlook [3] - BlackSky Technology Inc saw a 17.9% increase to $22.70 after Jefferies initiated coverage with a Buy rating and a price target of $23 [3] - Cytokinetics, Inc. shares rose by 11.2% to $69.74 after FDA approval of MYQORZO for treating adults with symptomatic obstructive hypertrophic cardiomyopathy [3]

Core Points - Cytokinetics held a conference call to discuss the FDA approval of MYQORZO [1] Group 1 - The conference call was led by Diane Weiser, the Senior Vice President of Corporate Affairs at Cytokinetics [1]